Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Nov 7, 2024
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025
Cash position of $167 million, with operating runway into the fourth quarter of 2026
Read more at globenewswire.comNASDAQ:BOLD (2/24/2025, 11:43:53 AM)
1.89
-0.07 (-3.57%)
Find more stocks in the Stock Screener
